

MEETING ABSTRACT



A nationwide survey of hereditary angioedema due to C1 inhibitor deficiency in Italy

Andrea Zanichelli^{1*}, Francesco Arcoleo², Maria Pina Barca³, Paolo Borrelli⁴, Maria Bova⁵, Mauro Cancian⁶, Marco Cicardi¹, Enrico Cillari², Caterina De Carolis⁶, Tiziana De Pasquale⁷, Isabella Del Corso⁸, Ilaria Massardo⁹, Paola Minale¹⁰, Vincenzo Montinaro¹¹, Sergio Neri¹², Roberto Perricone¹³, Stefano Pucci⁷, Paolina Quattrocchi¹⁴, Oliviero Rossi¹⁵, Massimo Triggiani¹⁶

From 3rd WAO International Scientific Conference (WISC) 2014 Rio de Janeiro, Brazil. 6-9 December 2014

Background

Hereditary angioedema due to C1-inhibitor deficiency (C1-INH-HAE type I) or dysfunction (C1-INH-HAE type II) is a rare disease characterized by recurrent episodes of edema with an estimated frequency of 1:50,000 in the global population without racial or gender differences. In this study we present the results of a nationwide survey of C1-INH-HAE patients referring to 17 Italian centers, the Italian network for C1-INH-HAE, ITACA

Methods

Italian patients diagnosed with C1-INH-HAE from 1973 to 2013 were included in the study. Diagnosis of C1-INH-HAE was based on family and/or personal history of recurrent angioedema without urticaria and on antigenic and/or functional C1-INH deficiency.

Results

983 patients (53% female) from 376 unrelated families were included in this survey. Since 1973, 63 (6%) patients diagnosed with C1-INH-HAE died and data from 3 patients were missing when analysis was performed. Accordingly, the minimum prevalence of HAE in Italy in 2013 is 920:59,394,000 inhabitants, equivalent to 1:64,935. Compared to the general population, patients are less represented in the early and late decades of life: men start reducing after the 5th decade and women after the 6th. Median age of patients is 45 (IQ 28-57), median age at diagnosis is 26 years (IQ 13-41). C1-INH-HAE type 1 are 87%, with median age at diagnosis of 25 (13-40); type 2 are

13% with median age at diagnosis of 31 (IQ 16-49). Functional C1INH is \leq 50% in 99% of patients. Antigen C1INH is \leq 50% in 99% of type 1. C4 is \leq 50% in 96% of patients.

Conclusions

This nationwide survey of C1-INH-HAE provides for Italy a prevalence of 1: 64,935. C1-INH-HAE patients listed in our database seem to have a shorter life expectancy than the general population. Since angioedema symptoms usually start during puberty, the estimated delay in diagnosis is higher than 10 years. The chance of having C1-INH-HAE with C4 plasma levels >50% is < 0.05.

Authors' details

¹Università Di Milano, Ospedale Luigi Sacco, Italy. ²Ospedali Riuniti Villa Sofia-Cervello, Italy. ³AUO Cagliari, Italy. ⁴Ospedale U. Parini, Aosta, Italy. ⁵A.O.U. Federico II, Napoli, Italy. ⁶Università Degli Studi Di Padova, Italy Azienda Ospedaliera San Giovanni-Addolorata Roma, Italy. ⁷Presidio Ospedaliero Di Civitanova Marche, Italy. ⁸Azienda Ospedaliera Universitaria Pisana (AOUP), Italy. ⁹Università Degli Studi Di Firenze, Italy. ¹⁰Irccs San Martino, Genova, Italy. ¹¹Azienda Ospedaliero-Universitaria "Consorziale Policlinico" Bari, Italy. ¹²Policlinico Universitario Di Catania, Italy. ¹³Policlinico Tor Vergata, Roma, Italy. ¹⁴Policlinico Universitario, Messina, Italy. ¹⁵Aou Careggi, Firenze, Italy. ¹⁶Universita Degli Studi Di Napoli, Italy.

Published: 8 April 2015

doi:10.1186/1939-4551-8-S1-A184 Cite this article as: Zanichelli *et al.*: A nationwide survey of hereditary angioedema due to C1 inhibitor deficiency in Italy. *World Allergy Organization Journal* 2015 8(Suppl 1):A184.

¹Università Di Milano, Ospedale Luigi Sacco, Italy

Full list of author information is available at the end of the article



© 2015 Zanichelli et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.